Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bolland

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
BMJ Open|November 1, 2019
An investigation into the impact and implications of published papers from retracted research: systematic search of affected literatureAlison Avenell, Fiona Stewart, Andrew Grey, et al.
The Journal of Clinical Endocrinology and Metabolism|February 5, 2010
Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysisShyam Sankaran, Greg Gamble, Mark Bolland, et al.
The Journal of Clinical Endocrinology and Metabolism|February 5, 2020
Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized TrialAndrew Grey, Anne Horne, Greg Gamble, et al.
Calcified Tissue International|July 8, 2011
Familial Paget disease and SQSTM1 mutations in New ZealandTim Cundy, Dorit Naot, Usha Bava, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 26, 2010
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trialAndrew Grey, Mark Bolland, Diana Wattie, et al.
The Journal of Clinical Endocrinology and Metabolism|November 11, 2011
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trialAndrew Grey, Mark Bolland, Sumwai Wong, et al.
European Journal of Endocrinology|March 13, 2012
Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trialAndrew Grey, Vaughan Beckley, Anthony Doyle, et al.
Addiction (Abingdon, England)|October 20, 2010
Decreased bone density in men on methadone maintenance therapyAndrew Grey, Karla Rix-Trott, Anne Horne, et al.
The American Journal of Clinical Nutrition|July 25, 2014
Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysisJohn A Ford, Graeme S MacLennan, Alison Avenell, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 2007
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trialAndrew Grey, Mark Bolland, Greg Gamble, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
BMJ Open|November 1, 2019
An investigation into the impact and implications of published papers from retracted research: systematic search of affected literatureAlison Avenell, Fiona Stewart, Andrew Grey, et al.
The Journal of Clinical Endocrinology and Metabolism|February 5, 2010
Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysisShyam Sankaran, Greg Gamble, Mark Bolland, et al.
The Journal of Clinical Endocrinology and Metabolism|February 5, 2020
Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized TrialAndrew Grey, Anne Horne, Greg Gamble, et al.
Calcified Tissue International|July 8, 2011
Familial Paget disease and SQSTM1 mutations in New ZealandTim Cundy, Dorit Naot, Usha Bava, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 26, 2010
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trialAndrew Grey, Mark Bolland, Diana Wattie, et al.
The Journal of Clinical Endocrinology and Metabolism|November 11, 2011
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trialAndrew Grey, Mark Bolland, Sumwai Wong, et al.
European Journal of Endocrinology|March 13, 2012
Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trialAndrew Grey, Vaughan Beckley, Anthony Doyle, et al.
Addiction (Abingdon, England)|October 20, 2010
Decreased bone density in men on methadone maintenance therapyAndrew Grey, Karla Rix-Trott, Anne Horne, et al.
The American Journal of Clinical Nutrition|July 25, 2014
Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysisJohn A Ford, Graeme S MacLennan, Alison Avenell, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 2007
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trialAndrew Grey, Mark Bolland, Greg Gamble, et al.
Pageof 5